Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: Implications for HIV Associated Neurocognitive Disorders (HAND)

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Brown, Lecia A M ^a   Jin, Jingji ^a   Ferrell, Darren ^a   Sadic, Edin ^a   Obregon, Demian ^b   Smith, Adam J ^b   Tan, Jun ^a,b,c   Giunta, Brian ^a,c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE 1; EFAVIRENZ; LAMIVUDINE; ZIDOVUDINE; AMYLOID BETA PROTEIN; BENZOXAZINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SECRETASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PHAGOCYTOSIS; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; HIV ASSOCIATED DEMENTIA; IN VITRO STUDY; IN VIVO STUDY; MICROENVIRONMENT; MICROGLIA; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; REGULATORY MECHANISM; ANIMAL; CELL LINE; COGNITION DISORDERS; COMPLICATION; DRUG EFFECTS; FEMALE; HIV INFECTIONS; HUMAN; METABOLISM; PHAGOCYTOSIS;

AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BENZOXAZINES; CELL LINE; COGNITION DISORDERS; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MICE; OXIDATIVE STRESS; PHAGOCYTOSIS; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 84899710769     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095500     Document Type: Article

References (79)

1. Schouten EJ, Jahn A, Ben-Smith A, Makombe SD, Harries AD, et al. (2011) Antiretroviral drug supply challenges in the era of scaling up ART in Malawi. J Int AIDS Soc 14 Suppl 1: S4.
2. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, et al. (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17: 3-16.
3. Ciccarelli N, Fabbiani M, Di Giambenedetto S, Fanti I, Baldonero E, et al. (2011) Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 76: 1403-1409.
4. Winston A, Duncombe C, Li PC, Gill JM, Kerr SJ, et al. (2010) Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis 50: 920-929.
5. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, et al. (2007) The prevalence and incidence of neurocognitive impairment in the HAART era. Aids 21: 1915-1921. (Pubitemid 47329768)
6. Velasco M, Pareja JA, Losa JE, Valverde JF, Espinosa A, Gujarro C Dream changes following initiation of efavirenz treatment. Med Clin (Barc) 136: 103-105.
7. Waters L, Fisher M, Winston A, Higgs C, Hadley W, et al. (2001) A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS 25: 65-71.
8. Romao PR, Lemos JC, Moreira J, de Chaves G, Moretti M, et al., (2011) Anti-HIV drugs nevirapine and efavirenz affect anxiety-related behavior and cognitive performance in mice. Neurotox Res 19: 73-80.
9. Wintergerst U, Hoffmann F, Jansson A, Notheis G, Huss K, et al. (2008) Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children. J Antimicrob Chemother 61: 1336-1339. (Pubitemid 351753604)
10. Sambamurti K, Greig NH, Lahiri DK (2002) Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Med 1: 1-31. (Pubitemid 37021521)
11. Golde TE, Eckman CB, Younkin SG (2000) Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim Biophys Acta 1502: 172-187. (Pubitemid 30433866)
12. Huse JT, Doms RW (2000) Closing in on the amyloid cascade: recent insights into the cell biology of Alzheimer's disease. Mol Neurobiol 22: 81-98. (Pubitemid 32545343)
13. Selkoe DJ (1996) Cell biology of the beta-amyloid precursor protein and the genetics of Alzheimer's disease. Cold Spring Harb Symp Quant Biol 61: 587-596.
14. Bradt BM, Kolb WP, Cooper NR (1998) Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med 188: 431-438. (Pubitemid 28369133)
15. Suo Z, Tan J, Placzek A, Crawford F, Fang C, et al. (1998) Alzheimer's beta-amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40. Brain Res 807: 110-117. (Pubitemid 29005242)
16. Murakami K, Irie K, Ohigashi H, Hara H, Nagao M, et al. (2005) Formation and stabilization model of the 42-mer Abeta radical: implications for the long-lasting oxidative stress in Alzheimer's disease. J Am Chem Soc 127: 15168-15174. (Pubitemid 41547384)
17. Schenk D, Games KD, McConlogue L (1995) The potential utility of transgenic mice harboring beta-amyloid precursor protein. Neurobiol Aging 16: 711-713; discussion 715-718.
18. Sinha S, Lieberburg I (1999) Cellular mechanisms of beta-amyloid production and secretion. Proc Natl Acad Sci U S A 96: 11049-11053. (Pubitemid 29487325)
19. Steiner H, Capell A, Haass C (1999) Proteolytic processing and degradation of Alzheimer's disease relevant proteins. Biochem Soc Trans 27: 234-242. (Pubitemid 29086041)
20. De Strooper B, Beullens M, Contreras B, Levesque L, Craessaerts K, et al. (1997) Phosphorylation, subcellular localization, and membrane orientation of the Alzheimer's disease-associated presenilins. J Biol Chem 272: 3590-3598.
21. Jacobsen JS, Reinhart P, Pangalos MN (2005) Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. NeuroRx 2: 612-626. (Pubitemid 41393269)
22. Cossarizza A, Moyle G (2004) Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 18: 137-151. (Pubitemid 38253435)
23. Apostolova N, Blas-Garcia A, Esplugues JV (2011) Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-gamma inhibition. Trends Pharmacol Sci 32: 715-725.
24. Apostolova N, Blas-Garcia A, Esplugues JV (2011) Mitochondrial toxicity in HAART: an overview of in vitro evidence. Curr Pharm Des 17: 2130-2144.
25. Apostolova N, Gomez-Sucerquia LJ, Gortat A, Blas-Garcia A, Esplugues JV (2011) Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy. Hepatology 54: 1009-1019.
26. Blas-Garcia A, Esplugues JV, Apostolova N (2011) Twenty years of HIV-1 non-nucleoside reverse transcriptase inhibitors: time to reevaluate their toxicity. Curr Med Chem 18: 2186-2195.
27. Blas-Garcia A, Apostolova N, Esplugues JV (2011) Oxidative stress and mitochondrial impairment after treatment with anti-HIV drugs: clinical implications. Curr Pharm Des 17: 4076-4086.
28. Manda KR, Banerjee A, Banks WA, Ercal N (2011) Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood-brain barrier endothelial cells. Free Radic Biol Med 50: 801-810.
29. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, et al. (2008) Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358: 2095-2106. (Pubitemid 351679596)
30. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, et al. (1999) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 341: 1865-1873.
31. Hirschel B, Calmy (2008) A Initial treatment for HIV infection - an embarrassment of riches. N Engl J Med 358: 2170-2172.
32. Apostolova N, Gomez-Sucerquia LJ, Alegre F, Funes HA, Victor VM, et al. (2013) ER stress in human hepatic cells treated with Efavirenz: mitochondria again. J Hepatol 59: 780-789.
33. Apostolova N, Gomez-Sucerquia LJ, Gortat A, Blas-Garcia A, Esplugues JV (2011) Autophagy as a rescue mechanism in efavirenz-induced mitochondrial dysfunction: a lesson from hepatic cells. Autophagy 7: 1402-1404.
34. Blas-Garcia A, Apostolova N, Ballesteros D, Monleon D, Morales JM, et al. (2010) Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology 52: 115-125.
35. Rodrigue KM, Rieck JR, Kennedy KM, Devous MD, Sr., Diaz-Arrastia R, et al. (2010) Risk factors for beta-amyloid deposition in healthy aging: vascular and genetic effects. JAMA Neurol 2013; 70: 600-606.
36. Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE (2006) Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy. Acta Neuropathol 111: 529-538. (Pubitemid 43778957)
37. Achim CL, Adame A, Dumaop W, Everall IP, Masliah E (2009) Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J Neuroimmune Pharmacol 4: 190-199.
38. Brew BJ, Pemberton L, Blennow K, Wallin A, Hagberg L (2005) CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology 65: 1490-1492. (Pubitemid 41552790)
39. Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, et al. (2005) Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 19: 407-411. (Pubitemid 40446187)
40. Alisky JM (2007) The coming problem of HIV-associated Alzheimer's disease. Med Hypotheses 69: 1140-1143.
41. Esiri MM, Biddolph SC, Morris CS (1998) Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry 65: 29-33. (Pubitemid 28302353)
42. Clifford DB, Fagan AM, Holtzman DM, Morris JC, Teshome M, et al. (2009) CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology 73: 1982-1987.
43. Kiebala M, Polesskaya O, Yao Z, Perry SW, Maggirwar SB (2010) Nuclear factor-kappa B family member RelB inhibits human immunodeficiency virus-1 Tat-induced tumor necrosis factor-alpha production. PLoS One5: e11875.
44. Giunta B, Ehrhart J, Obregon DF, Lam L, Le L, et al. (2011)Antiretroviral medications disrupt microglial phagocytosis of beta-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders. Mol Brain 4: 23.
45. Lewis W, Kohler JJ, Hosseini SH, Haase CP, Copeland WC, et al. (2006) Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. AIDS 20: 675-684. (Pubitemid 43884294)
46. Chandra S, Murthy SN, Mondal D, Agrawal KC (2009) Therapeutic effects of Nigella sativa on chronic HAART-induced hyperinsulinemia in rats. Can J Physiol Pharmacol 87: 300-309.
47. Torres SM, Divi RL, Walker DM, McCash CL, Carter MM, et al. (2010) In utero exposure of female CD-1 mice to AZT and/or 3TC: II. Persistence of functional alterations in cardiac tissue. Cardiovasc Toxicol 10: 87-99.
48. Torres SM, Divi RL, Walker DM, McCash CL, Carter MM, et al. (2010) In utero exposure of female CD-1 mice to AZT and/or 3TC: II. Persistence of functional alterations in cardiac tissue. Cardiovasc Toxicol 10: 87-99.
49. Balani SK, Kauffman LR, deLuna FA, Lin JH (1999) Nonlinear pharmacokinetics of efavirenz (DMP-266), a potent HIV-1 reverse transcriptase inhibitor, in rats and monkeys. Drug Metab Dispos 27: 41-45. (Pubitemid 29060998)
50. Giunta B, Hou H, Zhu Y, Rrapo E, Tian J, et al. (2009) HIV-1 Tat contributes to Alzheimer's disease-like pathology in PSAPP mice. Int J Clin Exp Pathol 2: 433-443.
51. Giunta B, Hou H, Zhu Y, Salemi J, Ruscin A, et al. (2010) Fish oil enhances anti-amyloidogenic properties of green tea EGCG in Tg2576 mice. Neurosci Lett 471: 134-138.
52. Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, et al. (2008) Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. J Neurochem 104: 683-695.
53. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, et al. (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8: 79-84. (Pubitemid 41236735)
54. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, et al. (2007) Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64: 354-362. (Pubitemid 46425689)
55. Gomez-Sucerquia LJ, Blas-Garcia A, Marti-Cabrera M, Esplugues JV, Apostolova N (2012) Profile of stress and toxicity gene expression in human hepatic cells treated with Efavirenz. Antiviral Res 94: 232-241.
56. Pizzo PA, Eddy J, Falloon J, Balis FM, Murphy RF, et al. (1988) Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med 319: 889-896.
57. Rausch DM, Heyes M, Eiden LE (1994) Effects of chronic zidovudine administration on CNS function and virus burden after perinatal SIV infection in rhesus monkeys. Adv Neuroimmunol 4: 233-237. (Pubitemid 24325868)
58. Schmitt FA, Bigley JW, McKinnis R, Logue PE, Evans RW, et al. (1988) Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med 319: 1573-1578. (Pubitemid 19003423)
59. Selkoe DJ (2001) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 3: 75-80.
60. Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, et al. (2008) Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci 28: 4231-4237.
61. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, et al. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539. (Pubitemid 34288854)
62. Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ (2002) Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 30: 552-557. (Pubitemid 35001597)
63. Walsh DM, Klyubin I, Shankar GM, Townsend M, Fadeeva JV, (2005) The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans 33: 1087-1090. (Pubitemid 41659119)
64. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, et al. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99-102. (Pubitemid 26332733)
65. Dragicevic N, Smith A, Lin X, Yuan F, et al. (2011) Green tea epigallocatechin-3-gallate (EGCG) and other flavonoids reduce Alzheimer's amyloid-induced mitochondrial dysfunction. J Alzheimers Dis 26: 507-521.
66. Mandrekar S, Jiang Q, Lee CY, Koenigsknecht-Talboo J, Holtzman DM, et al. (2009) Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci 29: 4252-4262.
67. Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958-969.
68. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, et al. (2008) Hyman BT Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451: 720-724. (Pubitemid 351220570)
69. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, et al. (2010) YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 68: 903-912.
70. Okonkwo OC, Mielke MM, Griffith HR, Moghekar AR, O'Brien RJ, et al. (2011) Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment. Arch Neurol 68: 113-119.
71. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, et al. (2009) Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 1: 371-380.
72. Fagan AM, Head D, Shah AR, Marcus D, Mintun M, et al. (2009) Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 65: 176-183.
73. Grimmer T, Riemenschneider M, Forstl H, Henriksen G, Klunk WE, et al. (2009) Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 65: 927-934.
74. Liu Y, Jones M, Hingtgen CM, Bu G, Laribee N, et al. (2000) Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat Med 6: 1380-1387. (Pubitemid 32001023)
75. Gisslen M, Krut J, Andreasson U, Blennow K, Cinque P, et al. (2009) Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol 9: 63.
76. Ances BM, Christensen JJ, Teshome M, Taylor J, Xiong C, A et al. (2010) Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: a case-control study. Neurology 75: 111-115.
77. Ances BM, Benzinger TL, Christensen JJ, Thomas J, Venkat R, et al. (2012) 11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder. Arch Neurol 69: 72-77.
78. Wynn HE, Brundage RC, Fletcher CV (2002) Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 16: 595-609.
79. Gibbs JE, Gaffen Z, Thomas SA (2006) Nevirapine uptake into the central nervous system of the Guinea pig: an in situ brain perfusion study. J Pharmacol Exp Ther 317: 746-751.